血清生物标志物（FGF-2、HGF、MIF 和 PTN）在睾丸生殖细胞癌患者中的评估。
Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer.
机构信息
Universitätsklinikum Bonn, Klinik und Poliklinik für Urologie und Kinderurologie, Bonn, Germany
Universitätsklinikum Bonn, Klinik und Poliklinik für Urologie und Kinderurologie, Bonn, Germany.
出版信息
In Vivo. 2019 Nov-Dec;33(6):1935-1940. doi: 10.21873/invivo.11688.
BACKGROUND/AIM: FGF-2, HGF, MIF and PTN have been suggested as biomarkers for testicular germ cell cancer patients in earlier studies. Our study was designed to validate these potential novel tumor markers.
MATERIALS AND METHODS
Serum FGF-2, HGF, MIF and PTN levels were analysed using an ELISA technique in a screening cohort of 20 testicular germ cell cancer patients and 10 healthy men. MIF levels were measured in a validation cohort of 84 patients with testicular cancer, 24 with non-malignant testicular tumors and 64 healthy men.
RESULTS
Serum FGF-2, HGF and PTN levels did not differ in cancer patients and healthy males within the screening cohort, whereas MIF was significantly increased among cancer patients. Within the validation cohort, a modest but insignificant increase of serum MIF was observed in TGCT patients compared to healthy men. MIF levels were not correlated with adverse clinical-pathological parameters.
CONCLUSION
FGF-2, HGF, MIF and PTN are not suitable as non-invasive biomarkers for testicular germ cell cancer patients.
背景/目的：在之前的研究中，FGF-2、HGF、MIF 和 PTN 被认为是睾丸生殖细胞癌患者的生物标志物。本研究旨在验证这些潜在的新型肿瘤标志物。
材料和方法
使用 ELISA 技术分析了 20 例睾丸生殖细胞癌患者和 10 例健康男性的血清 FGF-2、HGF、MIF 和 PTN 水平。在 84 例睾丸癌患者、24 例非恶性睾丸肿瘤患者和 64 例健康男性的验证队列中测量了 MIF 水平。
结果
在筛选队列中，癌症患者和健康男性的血清 FGF-2、HGF 和 PTN 水平没有差异，而 MIF 在癌症患者中显著升高。在验证队列中，与健康男性相比，TGCT 患者的血清 MIF 略有但无统计学意义的升高。MIF 水平与不良临床病理参数无关。
结论
FGF-2、HGF、MIF 和 PTN 不适合作为睾丸生殖细胞癌患者的非侵入性生物标志物。
Zotero 插件